AMG 160: A PSMA-targeted, bispecific T-cell engager immune therapy for mCRPC

Bookmark and Share
Published: 22 Sep 2020
Views: 835
Rating:
Save
Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia

Dr Ben Tran spoke to ecancer online about AMG 160 presented at the ESMO 2020 Virtual Congress.

He initially outlined the mechanism of AMG 160 and why there is a need for these types of immune therapies.

Dr Tran went into detail regarding the toxicities for AMG 160, which revolved around the management of cytokine release syndrome.

Dr Tran wrapped up with their expectations for the future of this work, and the potential place AMG 160 could sit in the treatment landscape of mCRPC.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.